ARA-290

ARA-290 (also known as Cibinetide, ARA290, Cyclic helix B peptide) is a prominently researched experimental compound classified strictly within the EPO Receptor Agonist framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it selectively activates the innate repair receptor (IRR), a heterodimer of the erythropoietin receptor (EPOR) and CD131 (βc receptor). Unlike full erythropoietin, ARA-290 binds only the IRR and not the classical erythropoietic homodimer receptor, conferring tissue-protective and anti-inflammatory effects without affecting red blood cell production, hematocrit, or platelet aggregation. Reduces corneal nerve fiber loss and improves small fiber neuropathy symptoms. with a documented biological half-life of roughly 0.033 hours, In preclinical investigative trials and independent academic studies, researchers utilizing ARA-290 have documented significant, quantifiable biological outcomes, primarily focusing on neuropathic pain relief, small fiber neuropathy, anti-inflammation, tissue protection. Typical research protocols investigate administering 4000 to 4000mcg via subq pathways daily x 28 days. However, it is critically important to understand that while ARA-290 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.